Annie Wong-Beringer, PharmD, FCCP, FIDSA
Clinical Pharmacy and Pharmaceutical Economics & Policy
Phone: (323) 442-1356
Fax: (626) 628-3024
|Web:||Anti-Infective Pharmacology Research|
Infectious diseases pharmacotherapy, antimicrobial resistance, antifungal therapy
Dr. Wong-Beringer has recently joined the faculty at the University of Southern California School of Pharmacy in July 2003 as an Associate Professor of Clinical Pharmacy. She is a graduate of USC School of Pharmacy. She received her postdoctoral residency in pharmacy practice and fellowship training in infectious diseases pharmacotherapy at the University of California, San Francisco. Her clinical practice and research is at Huntington Hospital, Pasadena.
Dr. Wong-Beringer has been a principal investigator on a number of research studies on antimicrobial resistance relating to extended-spectrum beta-lactamases and most recently, efflux-mediated resistance in Pseudomonas aeruginosa. She is also actively investigating the aerosolization potential of antifungal agents. Dr. Wong-Beringer has authored a number of journal articles and book chapters in the area of her clinical expertise and research.
Click here for:
Selected Projects/PublicationsWong-Beringer A. Extended-spectrum Beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: clinical and therapeutic implications. Pharmacotherapy 2001;21:583-92.
Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee NP, Pegues DA, Quinn JP, Bush K. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazdime. Clin Infect Dis 2002;34:135-146.
Wong-Beringer A, Liao C, Nguyen M, Pallares J. Applying patient selection criteria for drotrecogin alfa therapy in practice. Am J Health System Pharm 2003;60:1345-52.
Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003 (in press).